Matrix metalloproteinases function in the remodeling of the extracellular matrix during growth and development as well as in injury and disease processes. We examined the role of matrix metalloproteinase-9 in a model of olfactory nerve injury in mice. We measured changes in matrix metalloproteinase-9 protein levels for up to 60 days following olfactory nerve transection. Matrix metalloproteinase-9 levels increased within hours after injury, peaked at day 1 and were elevated for approximately 2 weeks before returning to control levels over the 60-day time period. The increase in matrix metalloproteinase-9 was temporally associated with the degeneration of olfactory neurons that follows nerve transection and with increased gliosis. Our results demonstrate a temporal relationship between matrix metalloproteinase-9 elevation, degeneration of olfactory neurons and gliosis.
Matrix metalloproteineases are associated with extracellular remodeling that occurs in injury and repair processes in the central nervous system (CNS). We examined the role of MMP-2 in a model of olfactory nerve injury and found that MMP-2 levels increased several hours following injury, peaked at day 7 and then decreased rapidly. We previously reported a rapid increase in MMP-9, within 5 h after nerve injury, corresponding to neuronal degeneration and increased glial activity. In this study, we show that MMP-2 peaks later than MMP-9, at the onset of neuronal regeneration and repair. Using MMP-9 knockout mice, we determined that the MMP-2 increase is independent of MMP-9. Our data suggest that MMP-2 and MMP-9 may play different roles in the injury and repair processes.
Betaine aldehyde dehydrogenase (BADH), the terminal enzyme of the glycine betaine synthetic pathway was purified 245-fold from the mitochondria of Atlantic and Chesapeake Bay oyster populations acclimated to 350 mosm, using ammonium sulfate precipitation, anion exchange, and affinity chromatography. BADH from both populations functions at its maximum rate at 50-55 degrees C over a broad pH range (7.5-9). BADH activity is also modulated by increased [Na(+)] and [K(+)]. Although BADH from both populations has a similar V(max), BADH from Bay oysters has a substantially lower affinity for its substrate, betaine aldehyde, (K(m) = 0.36 mM), than BADH from Atlantic oysters (K(m) = 0.1 mM). Despite kinetic differences, BADH from both Atlantic and Chesapeake Bay oysters have the same molecular weight based on electrophoretic analysis. These differences in BADH enzyme kinetics between the two oyster populations probably partially explain the lower glycine betaine synthesis rates and concentrations in Chesapeake Bay oysters. J. Exp. Zool. 286:238-249, 2000.
Choline dehydrogenase (CD), the first enzyme of the glycine betaine synthetic pathway, was measured in a mitochondrial lysate from gill tissue from Atlantic and Chesapeake Bay oysters acclimated to both 350 and 750 mosm. CD from both populations functions at its maximum rate at 30 degrees C and pH 8.75. Although CD from both populations has a similar affinity for its substrate, choline (K(m) = 15.7 mM), CD V(max) from Atlantic oysters is twice that from Bay oysters. In addition, the CD K(m )doubles and the V(max) increases four-fold in both oyster populations acclimated to 750 mosm. CD activity is competitively inhibited by both betaine aldehyde and glycine betaine. The differences in CD kinetics between the two oyster populations help to account for the lower glycine betaine synthesis rates and concentrations in Chesapeake Bay oysters. CD cannot function rapidly enough to saturate the enzyme, betaine aldehyde dehydrogenase (BADH), immediately downstream, and, therefore, CD kinetics limit the rate of glycine betaine synthesis in oysters. J. Exp. Zool. 286:250-261, 2000.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.